Accuray
Accuray's revenue fell 12.3% to $402 million in fiscal 2026. Its operating margin was −6.6%, down from 1.7% a year earlier. Free cash flow was −$13 million. The diluted share count rose 19.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Accuray does
Accuray makes radiation therapy machines that hospitals and cancer centers use to treat tumors, along with the software to plan treatments and the imaging that guides them. Its two product families are the CyberKnife, a robotic system used for highly focused treatments of tumors anywhere in the body, including the brain and spine, and a line of helical systems (Accuray Stellar, Radixact, Accuray Helix and Tomo C) that deliver radiation in a spiral around the patient.
The company earns money in two ways: selling systems and upgrades, which are large, one-off purchases with long sales and installation cycles, and selling services such as maintenance, support and training to customers who already own its machines. It sells directly in the United States and much of Europe and Asia, and through distributors elsewhere. A joint venture in China that makes and sells its systems there accounted for about 16% of net revenue in the year to June 30, 2026. Accuray says the market for new machines is dominated by Varian, part of Siemens Healthineers, and Elekta.
It builds its systems in Madison, Wisconsin, where it is based, and makes the part that produces the radiation beam in Chengdu, China. It had 809 employees at June 30, 2026, nearly half of them outside the United States.
Its biggest risks, as it describes them
- Its machines may not win wide enough acceptance from hospitals to support the business, against much larger rivals.
- High-priced systems with long and uneven sales cycles make revenue and cash flow hard to predict.
- Its debt, and past breaches of loan conditions that needed waivers from its lenders.
- Relying on single suppliers for key parts, and on distributors and a joint venture to sell in many countries, including China.
- Tariffs and trade tensions that have already cut its sales in China and its margins.
Income statement
Accuray lost money in fiscal 2026: a net loss of $49 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | 89 | 89 | 69 | 57 | 41 |
| Debt incl. finance leases | 189 | 183 | 180 | 149 | — |
| Net debt (negative means net cash) | 100 | 94 | 111 | 92 | — |
| Net debt to EBITDA | 7.3x | 13.6x | 17.4x | 6.6x | — |
| Debt to equity | 3.5x | 3.4x | 4.0x | 1.8x | — |
| Interest coverage | 1.0x | 0.2x | 0.0x | 0.6x | −0.8x |
| Current ratio | 1.7x | 1.7x | 1.7x | 1.6x | 1.5x |
| Quick ratio | 1.0x | 1.0x | 0.9x | 0.9x | 0.7x |
Cash flow
Projections
Project Accuray's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $134,146 of Accuray shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Feb 20, 2026 | Steven F MayerDirector | Bought | 54,875 | $0.56 | $30,730 | Form 4 |
| Feb 19, 2026 | Steven F MayerDirector | Bought | 69,000 | $0.53 | $36,570 | Form 4 |
| Feb 18, 2026 | Steven F MayerDirector | Bought | 126,125 | $0.53 | $66,846 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 | FY26 |
|---|---|---|---|
| Piotroski F-score | 2 of 9 | 6 of 9 | — |
| Rule of 40 | −3.7% | 2.4% | −15.5% |
| Altman Z'' | −1.69 | −1.53 | −3.04 |
| Accruals ratio | −0.8% | −0.9% | −9.2% |
The nine F-score tests
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Fail |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | 2 of 9 | 6 of 9 | — |
Compare
Put Accuray side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Accuray | FY26 | −12.3% | −6.6% | −3.2% | — | — | — | |
| MiMedx Group | FY25 | 20.0% | 15.3% | — | 43.3% | −1.9x | 7 | Compare |
| InMode | FY25 | −6.2% | 23.1% | 22.8% | — | — | — | Compare |
| Artivion | FY25 | 13.6% | 7.7% | 0.2% | 3.9% | 2.7x | 7 | Compare |
| Inogen | FY25 | 3.9% | −8.7% | −3.9% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 383 | 405 | 419 | 383 | 396 | 430 | 448 | 447 | 458 | 402 |
| Revenue growth | −3.9% | 5.6% | 3.4% | −8.6% | 3.5% | 8.5% | 4.1% | −0.2% | 2.7% | −12.3% |
| Gross profit | 141 | 162 | 163 | 150 | 160 | 160 | 154 | 143 | 147 | 112 |
| Research and development | 50 | 57 | 56 | 50 | 53 | 58 | 57 | 50 | 48 | 38 |
| Operating income | −10 | −4 | 1 | 12 | 22 | 8 | 2 | 0 | 8 | −26 |
| Net income | −30 | −24 | −16 | 4 | −6 | −5 | −9 | −16 | −2 | −49 |
| Diluted EPS (US$) | −0.36 | −0.28 | −0.19 | 0.04 | −0.07 | −0.06 | −0.10 | −0.16 | −0.02 | — |
| Diluted shares (millions) | 82 | 85 | 88 | 91 | 92 | 92 | 95 | 98 | 103 | 123 |
| Cash flow | ||||||||||
| Cash from operations | −0 | 18 | −30 | −2 | 38 | −2 | 16 | −12 | 3 | −7 |
| Capital expenditure | 5 | 6 | 4 | 4 | 2 | 5 | 13 | 4 | 4 | 6 |
| Free cash flow | −5 | 12 | −34 | −5 | 36 | −7 | 3 | −16 | −1 | −13 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 14 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 14 | 12 | 11 | 8 | 9 | 11 | 10 | 10 | 10 | 6 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 96 | — | 77 | 108 | 116 | 89 | 89 | 69 | 57 | 41 |
| Debt incl. finance leases | 165 | 131 | 160 | 189 | 178 | 189 | 183 | 180 | 149 | — |
| Total assets | 406 | 379 | 438 | 491 | 480 | 473 | 479 | 469 | 470 | 444 |
| Total liabilities | 360 | 330 | 388 | 427 | 411 | 420 | 426 | 424 | 389 | 402 |
| Shareholders' equity | 46 | 49 | 50 | 64 | 69 | 53 | 54 | 45 | 81 | 42 |
| Margins and ratios | ||||||||||
| Gross margin | 36.9% | 39.9% | 38.8% | 39.1% | 40.2% | 37.2% | 34.4% | 32.0% | 32.0% | 27.7% |
| Operating margin | −2.6% | −0.9% | 0.1% | 3.3% | 5.6% | 1.9% | 0.5% | 0.1% | 1.7% | −6.6% |
| Net margin | −7.7% | −5.9% | −3.9% | 1.0% | −1.6% | −1.2% | −2.1% | −3.5% | −0.3% | −12.2% |
| Free cash flow margin | −1.4% | 3.0% | −8.1% | −1.3% | 9.1% | −1.7% | 0.7% | −3.5% | −0.3% | −3.2% |
| Rule of 40 (growth + FCF margin) | −5.3% | 8.6% | −4.7% | −9.9% | 12.6% | 6.8% | 4.8% | −3.7% | 2.4% | −15.5% |
| Return on capital | −7.1% | — | — | 6.1% | 12.8% | 4.5% | 1.2% | 0.3% | 2.4% | — |
| Return on equity | −55.7% | −50.2% | −33.4% | 6.7% | −9.5% | −8.8% | −17.4% | −31.5% | −2.5% | −80.1% |
| Return on assets | −6.8% | −6.1% | −4.0% | 0.8% | −1.3% | −1.1% | −1.9% | −3.3% | −0.3% | −10.8% |
| Net debt to EBITDA | 8.3x | — | 7.5x | 4.1x | 2.1x | 7.3x | 13.6x | 17.4x | 6.6x | — |